Treatment of "good risk" metastatic testicular cancer.
Garrow
G C
GC
Division of Medical Oncology, Vanderbilt University Medical Center, Vanderbilt Clinic, Nashville, TN 37232-5536.
Johnson
D H
DH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D012307:Risk Factors; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage
D014408:Biomarkers, Tumor; D001761:Bleomycin; D003609:Dactinomycin; D014747:Vinblastine; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin